GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProKidney Corp (MEX:PROK) » Definitions » Cyclically Adjusted PB Ratio

ProKidney (MEX:PROK) Cyclically Adjusted PB Ratio : (As of Jun. 22, 2024)


View and export this data going back to 2022. Start your Free Trial

What is ProKidney Cyclically Adjusted PB Ratio?

ProKidney does not have a history long enough to calculate Cyclically Adjusted Book per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PB Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


ProKidney Cyclically Adjusted PB Ratio Historical Data

The historical data trend for ProKidney's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProKidney Cyclically Adjusted PB Ratio Chart

ProKidney Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
- - - -

ProKidney Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ProKidney's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, ProKidney's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProKidney's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProKidney's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where ProKidney's Cyclically Adjusted PB Ratio falls into.



ProKidney Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

ProKidney does not have a history long enough to calculate Cyclically Adjusted Book per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PB Ratio for this company.


ProKidney  (MEX:PROK) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


ProKidney Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of ProKidney's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ProKidney (MEX:PROK) Business Description

Industry
Traded in Other Exchanges
Address
2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, NC, USA, 27103
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease.